Chiron to Release Earnings on Wednesday, April 25, 2001

Conference Call/Webcast to Follow



Apr 16, 2001, 01:00 ET from Chiron Corporation

    EMERYVILLE, Calif., April 16 /PRNewswire/ --
 Chiron Corporation (Nasdaq:   CHIR) today announced that its first quarter
 2001 financial results will be released on Wednesday April 25, 2001 at
 4:00 p.m. Eastern Daylight Time (EDT).
     Forty-five minutes later, at 4:45 p.m. EDT, as part of the Company's
 efforts to ensure full disclosure to all parties, Chiron will webcast an
 earnings discussion conference call live on the Company's internet site.  The
 call will be lead by Sean Lance, chairman and chief executive officer.
     To access the live call or the 3-day archive via the internet, please
 logon to http://www.chiron.com .  Please connect to the Company's website at
 least 15 minutes prior to the conference call to ensure adequate time for any
 software download that may be needed to hear the webcast.  Alternatively,
 please call 888-306-2701 (U.S.) or 706-634-2118 (international).  Replay is
 available approximately 2 hours after the call through 11:59 p.m. EDT,
 April 27, 2001.  To access the replay, please call 800-642-1687 (U.S.) or
 706-645-9291 (international).  The conference ID number is 703686.
 
     About Chiron
     Chiron Corporation, headquartered in Emeryville, California, is a leading
 biotechnology company that participates in three global healthcare markets:
 biopharmaceuticals, vaccines and blood testing.  The company is applying an
 integrated scientific approach to the development of innovative products for
 preventing and treating cancer and infection.  For more information about
 Chiron, visit the company's web site at www.chiron.com.
     This news release contains forward-looking statements that involve risks
 and uncertainties.  A full discussion of the company's operations and
 financial condition, including factors that may affect its business and future
 prospects, is contained in documents the company files with the SEC, such as
 form 10-Q and 10-K.  These documents identify important factors that could
 cause the company's actual performance to differ from current expectations,
 including the outcome of clinical trials, regulatory review, manufacturing
 capabilities and marketing effectiveness.
 
 

SOURCE Chiron Corporation
    EMERYVILLE, Calif., April 16 /PRNewswire/ --
 Chiron Corporation (Nasdaq:   CHIR) today announced that its first quarter
 2001 financial results will be released on Wednesday April 25, 2001 at
 4:00 p.m. Eastern Daylight Time (EDT).
     Forty-five minutes later, at 4:45 p.m. EDT, as part of the Company's
 efforts to ensure full disclosure to all parties, Chiron will webcast an
 earnings discussion conference call live on the Company's internet site.  The
 call will be lead by Sean Lance, chairman and chief executive officer.
     To access the live call or the 3-day archive via the internet, please
 logon to http://www.chiron.com .  Please connect to the Company's website at
 least 15 minutes prior to the conference call to ensure adequate time for any
 software download that may be needed to hear the webcast.  Alternatively,
 please call 888-306-2701 (U.S.) or 706-634-2118 (international).  Replay is
 available approximately 2 hours after the call through 11:59 p.m. EDT,
 April 27, 2001.  To access the replay, please call 800-642-1687 (U.S.) or
 706-645-9291 (international).  The conference ID number is 703686.
 
     About Chiron
     Chiron Corporation, headquartered in Emeryville, California, is a leading
 biotechnology company that participates in three global healthcare markets:
 biopharmaceuticals, vaccines and blood testing.  The company is applying an
 integrated scientific approach to the development of innovative products for
 preventing and treating cancer and infection.  For more information about
 Chiron, visit the company's web site at www.chiron.com.
     This news release contains forward-looking statements that involve risks
 and uncertainties.  A full discussion of the company's operations and
 financial condition, including factors that may affect its business and future
 prospects, is contained in documents the company files with the SEC, such as
 form 10-Q and 10-K.  These documents identify important factors that could
 cause the company's actual performance to differ from current expectations,
 including the outcome of clinical trials, regulatory review, manufacturing
 capabilities and marketing effectiveness.
 
 SOURCE  Chiron Corporation